A Phase 3, 52-week, open-label, single arm study to investigate the efficacy and safety of mepolizumab SC in participants aged 6 to 17 years with hypereosinophilic syndrome. - 215360

Glaxosmithkline Research & Development Limited0 个研究点目标入组 25 人开始时间: 2024年6月5日最近更新: 2024年7月22日

适应症

试验速览

阶段: 1 期
状态: 招募中
发起方: Glaxosmithkline Research & Development Limited
入组人数: 25

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 0 至 17（—）
性别: All

入选标准

•Participant must be aged 6 to 17 years inclusive, at Screening (Visit 1), Participants who have been diagnosed with HES for at least 6 months prior to enrolment (Visit 2), A history of 2 or more HES flares within the past 12 months prior to Screening (Visit 1), Participants must have blood eosinophil count =1000 cells/µL present at Screening, Participants must be on a stable dose of HES therapy for the 4 weeks prior to the first dose of mepolizumab (Visit 2), Male and/or female [(according to their reproductive organs and functions assigned by chromosomal complement)] [FDA, 2016]. • Contraception and barriers as well as pregnancy testing is required as appropriate for the age and sexual activity of paediatric participants and as required by local regulations. A female participant is eligible to participate if she is either: • Premenarcheal or • Not pregnant as confirmed by a negative urine (or serum if required by local regulations) human chorionic gonadotrophin [hCG] test if of reproductive potential. Females of childbearing potential must commit to consistent and correct use of an acceptable method of contraception (see Section 10.4, Appendix 4 of the study protoocol) for the duration of the trial and 16 weeks after the last dose of investigational product. A urine pregnancy test is required of females of childbearing potential., The investigator, or a person designated by the investigator, will obtain written informed consent from each study participant's (legal guardian as defined in Section 10.1.3 of the study protoocol) and the participant's assent, when applicable, before any study-specific activity is performed (unless a waiver of informed consent has been granted by an Institutional Review Board [IRB]/Ethics Committee [EC]). All legal guardians should be fully informed, and participants should be informed to the fullest extent possible, about the study in language and terms they are able to understand., The participant capable of providing signed and dated written assent signs and dates a written assent form (age appropriate) and the parent/guardian signs and dates a written informed consent form (ICF) for study participation prior to the initiation of any study-related activities., A legal guardian or primary caregiver must be available to help the study-site personnel ensure follow-up; support the participant to attended assessment days according to the SoA (e.g., able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures); consistently and consecutively be available to provide information on the participant using the rating scales during the scheduled study visits; accurately and reliably dispense study intervention as directed.

排除标准

•Life-threatening HES or life-threatening HES co-morbidities: Imminently lifethreatening HES disease severity such that (a) likelihood of death is high unless the course of the disease is interrupted within 12 weeks prior to Visit 2 (b) likelihood of severe deterioration of HES is high unless immediate therapeutic intervention is provided., Participants who are not responsive to OCS based on clinical response or blood eosinophil counts., Participants who have previously received mepolizumab in the 4 months prior to enrolment (Visit 2)., Participants receiving any of the following: • IV or SC corticosteroids in the 4-week period prior to enrolment (Visit 2). • Any other monoclonal antibodies within 30 days or 5 half-lives, whichever is longer, of enrolment (Visit 2)., Participants who have received treatment with an investigational agent (biologic or non-biologic) within the past 30 days or 5 drug halflives, whichever is longer, prior to enrolment (Visit 2). The term investigational applies to any drug not approved for sale in the country in which it is being used or investigational formulations of marketed products, Use of candidate COVID-19 vaccines that have not received limited, accelerated, or full authorisation/approval, and are only in use as part of a clinical trial, Participants who are currently participating in any other interventional clinical study, Participants with any history of hypersensitivity to any monoclonal antibody (including mepolizumab), 12-lead ECG finding: For all participants: • An abnormal ECG finding from the 12-lead ECG conducted at Visit 1 if considered to be clinically significant and would impact the participant's participation during the study based on the evaluation of the investigator. For participants aged 6 to 11 years: • QT interval corrected using Fridericia's formula (QTcF) > 450 msec. • Left bundle branch block For participant aged 12 to 17 years: • QTcF > 450 msec or QT interval corrected for heart rate (QTc) > 480 msec in participants with bundle branch block, Liver abnormality/disease, Other laboratory abnormalities, Other concurrent medical conditions that may affect the participant's safety: Participants who have known, pre-existing, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological, respiratory, or any other system abnormalities that are not associated with HES and are uncontrolled with standard treatment., Eosinophilia of unknown significance, FIP1L1-PDGFRa (F/P) Status: Participants who test positive for F/P, Clinical diagnosis of EGPA, Infection: • Participants with chronic or ongoing active infections requiring systemic treatment, as well as participants who have experienced clinically significant infections due to viruses, bacteria, and fungi within 4 weeks prior to enrolment (Visit 2). • Participants with a pre-existing parasitic infestation within 6 months prior to enrolment (Visit 2)., Participants with a known immunodeficiency (e.g., HIV), other than that explained by the use of OCS or other therapy taken for HES., Participants with documented history of any clinically significant cardiac damage prior to Screening (Visit 1) that, in the opinion of the investigator, would impact the participant's participation during the study., Malignancy: • Participants with a history of or current lymphoma • Participants with current malignancy or previous history of cancer in remission for less than 12 months prior to Scree

研究者

发起方

Glaxosmithkline Research & Development Limited

相似试验

招募中

1 期

Study in Paediatrics with HypEREosinophilic syndrome (SPHERE)Hypereosinophilic syndrome (HES)MedDRA version: 20.0Level: PTClassification code 10048643Term: Hypereosinophilic syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disorders

EUCTR2021-000933-15-NLGlaxoSmithKline Research & Development Limited25

尚未招募

3 期

A Phase 3, 52-week, open-label, single arm study to investigate the efficacy and safety of mepolizumab SC in participants aged 6 to 17 years with hypereosinophilic syndrome.

NL-OMON51313GlaxoSmithKline3

进行中（未招募）

3 期

A Phase 3 Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal DialysisHyperphosphatemia Patients on Peritoneal DialysisHyperphosphatemia, Peritoneal DialysisD054559

JPRN-jRCT2051200145Kinoshita Jun40

招募中

1 期

CTIS2022-502498-40-00293

招募中

3 期

A Phase 3b, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other luspatercept(ACE-536) clinical trials

JPRN-jRCT2031220422Hayakawa Jin18